泰林生物(300813.SZ):擬新設控股子公司 開展細胞技術相關業務
格隆匯2月3日丨泰林生物(300813.SZ)公佈,公司擬與王歡、嚴湘青、王豔紅、鬱嘯、李曉簽署《出資協議書》並設立合資公司北京多能細胞技術有限公司(暫定),開展細胞技術相關業務。公司董事、高管夏信羣與嚴湘青為夫妻關係,該次交易構成關聯交易。
合資公司註冊資本擬定為人民幣2000萬元,其中公司出資1100萬元,佔註冊資本的55%;王歡出資400萬元,佔註冊資本的20%;嚴湘青出資380萬元,佔註冊資本的19%;王豔紅出資50萬元,佔註冊資本的2.5%;鬱嘯出資50萬元,佔註冊資本的2.5%;李曉出資20萬元,佔註冊資本的1%。均為自有資金出資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.